What is PT-141?
PT-141, international name bremelanotide, is a synthetic cyclic heptapeptide that acts on melanocortin receptors, mainly MC4R and MC3R, in the brain. It was derived from Melanotan 2 and differs from it only at the C-terminal end: PT-141 ends in a free acid, Melanotan 2 in an amide.
PT-141 product specifications
- Compound: PT-141 (bremelanotide)
- Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH (7 residues)
- Molecular formula: C50H68N14O10
- Molecular weight: about 1025.2 g/mol
- Vial size: 10mg
PT-141 vs Melanotan 1 and Melanotan 2
- Melanotan 2: same cyclic core with a C-terminal amide; not approved anywhere.
- Melanotan 1 (afamelanotide): a longer, linear 13-amino-acid alpha-MSH analogue that acts mainly on MC1R in skin.
Regulatory status
Bremelanotide is the active ingredient of a prescription medicine approved in the US in 2019 (Vyleesi). This product is research material, not that medicine, and is sold for laboratory research use only.
Handling and research-use notice
Store and handle this material as stated on the label and certificate of analysis for your batch; see our guide to storing research peptides. This product is sold for laboratory research use only. It is not a medicine or supplement and is not for human or veterinary use.
